Last --
Change Today 0.00 / 0.00%
Volume 0.0
4552 On Other Exchanges
4552 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

jcr pharmaceuticals co ltd (4552) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for JCR PHARMACEUTICALS CO LTD (4552)

Related News

No related news articles were found.

jcr pharmaceuticals co ltd (4552) Related Businessweek News

No Related Businessweek News Found

jcr pharmaceuticals co ltd (4552) Details

JCR Pharmaceuticals Co., Ltd. engages in the research, development, manufacture, and sale of biopharmaceutical products based on recombinant DNA technologies primarily in Japan. Its product pipeline includes Follicle stimulating hormone, which is in Phase I/II clinical trials for the treatment of infertility; Alpha-galactosidase A that is in clinical trials to treat fabry and lysosomal storage diseases; and Iduronate-2-sulfatase, which is in the clinical trial in preparation stage for hunter syndrome. The company’s preclinical product pipeline comprises Darbopoietin Alfa to treat renal anemia, Glucocerebrosidase for gaucher disease, BBB-Penetrating Iduronate-2-sulfatase for the treatment of hunter syndrome, and Long-acting Somatropin for growth disorder treatment. It also develops cellular therapy products, including human mesenchymal stem cells for the treatment of graft-versus-host disease associated with hematopoietic stem cell transplantation. JCR Pharmaceuticals Co., Ltd. was founded in 1975 and is headquartered in Ashiya, Japan.

501 Employees
Last Reported Date: 06/24/15
Founded in 1975

jcr pharmaceuticals co ltd (4552) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

jcr pharmaceuticals co ltd (4552) Key Developments

JCR Pharmaceuticals Seeks Acquisitions

JCR Pharmaceuticals Co., Ltd. (TSE:4552) to be acquisitive. If the right store comes along we will look at it - Jonathan James, owner, JCR.

JCR Pharmaceuticals Co., Ltd. Presents at Mizuho Japan Opportunities 2016 Small Cap Conference, Mar-07-2016

JCR Pharmaceuticals Co., Ltd. Presents at Mizuho Japan Opportunities 2016 Small Cap Conference, Mar-07-2016 . Venue: Otemachi Tower, 1­5­5 Otemachi, Chiyoda­ku, Tokyo 100­8176, Japan.

JCR Pharmaceuticals Co., Ltd. Launches its Mesenchymal Stem Cell Product Temcell® HS Inj

Mesoblast Limited announced that its licensee in Japan, JCR Pharmaceuticals Co. Ltd. launched its mesenchymal stem cell product TEMCELL® HS Inj., for the treatment of acute graft versus host disease (aGVHD) in children and adults in Japan. TEMCELL is the first allogeneic cell therapy to be fully approved in Japan. The Japanese Government’s National Health Insurance set reimbursement for TEMCELL at ¥868,680 (approximately $7,700) per bag of 72 million cells. In Japan, the average adult patient is expected to receive at least 16 or up to 24 bags of 72 million cells. On this basis, Mesoblast expects a treatment course of TEMCELL in an adult Japanese patient to be reimbursed at a minimum of ¥13,898,880 (approximately $123,000) or up to ¥20,848,320 (approximately $185,000). Under its agreement with JCR, Mesoblast is entitled to receive royalties and other payments at predefined thresholds of cumulative net sales.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4552:JP ¥2,607.00 JPY -12.00

4552 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4552.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4552 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact JCR PHARMACEUTICALS CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at